HRP20110220T1 - Inhibitori kinaze - Google Patents
Inhibitori kinaze Download PDFInfo
- Publication number
- HRP20110220T1 HRP20110220T1 HR20110220T HRP20110220T HRP20110220T1 HR P20110220 T1 HRP20110220 T1 HR P20110220T1 HR 20110220 T HR20110220 T HR 20110220T HR P20110220 T HRP20110220 T HR P20110220T HR P20110220 T1 HRP20110220 T1 HR P20110220T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- group
- hetero
- cycloalkyl
- bicycloaryl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 31
- 206010012289 Dementia Diseases 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 150000001408 amides Chemical class 0.000 claims abstract 2
- 206010003246 arthritis Diseases 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 101
- 125000005842 heteroatom Chemical group 0.000 claims 56
- 125000000753 cycloalkyl group Chemical group 0.000 claims 49
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 31
- -1 cyano, thio, oxy, hydroxy, carbonyloxy Chemical group 0.000 claims 31
- 125000005843 halogen group Chemical group 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 21
- 150000001602 bicycloalkyls Chemical group 0.000 claims 19
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 14
- 125000003282 alkyl amino group Chemical group 0.000 claims 11
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 9
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- LWKMTSGBTDBNNY-UHFFFAOYSA-N 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-9h-pyrido[2,3-b]indole Chemical compound CCS(=O)(=O)C1=CC=CC(C=2C=3C4=CC(C)=CN=C4NC=3C(C)=CC=2)=C1 LWKMTSGBTDBNNY-UHFFFAOYSA-N 0.000 claims 1
- GZQUVLPYFQBCBP-UHFFFAOYSA-N 5-(3-ethylsulfonylphenyl)-8-methyl-9h-pyrido[2,3-b]indole Chemical compound CCS(=O)(=O)C1=CC=CC(C=2C=3C4=CC=CN=C4NC=3C(C)=CC=2)=C1 GZQUVLPYFQBCBP-UHFFFAOYSA-N 0.000 claims 1
- CMAJPRSIBKMYRC-UHFFFAOYSA-N 5-(3-ethylsulfonylphenyl)-9h-pyrido[2,3-b]indole Chemical compound CCS(=O)(=O)C1=CC=CC(C=2C=3C4=CC=CN=C4NC=3C=CC=2)=C1 CMAJPRSIBKMYRC-UHFFFAOYSA-N 0.000 claims 1
- XTEMRAFJCFBHFF-UHFFFAOYSA-N 5-(3-methoxyphenyl)-9h-pyrido[2,3-b]indole Chemical compound COC1=CC=CC(C=2C=3C4=CC=CN=C4NC=3C=CC=2)=C1 XTEMRAFJCFBHFF-UHFFFAOYSA-N 0.000 claims 1
- CMNRVZMJMRCXJI-UHFFFAOYSA-N 5-(3-methylphenyl)-9h-pyrido[2,3-b]indole Chemical compound CC1=CC=CC(C=2C=3C4=CC=CN=C4NC=3C=CC=2)=C1 CMNRVZMJMRCXJI-UHFFFAOYSA-N 0.000 claims 1
- WEOPAFKZSFLZAB-UHFFFAOYSA-N 5-(3-methylsulfonylphenyl)-9h-pyrido[2,3-b]indole Chemical compound CS(=O)(=O)C1=CC=CC(C=2C=3C4=CC=CN=C4NC=3C=CC=2)=C1 WEOPAFKZSFLZAB-UHFFFAOYSA-N 0.000 claims 1
- RGFSBLSURVONPK-UHFFFAOYSA-N 5-benzylsulfanyl-8-methyl-9h-pyrido[2,3-b]indole Chemical compound C1=2C3=CC=CN=C3NC=2C(C)=CC=C1SCC1=CC=CC=C1 RGFSBLSURVONPK-UHFFFAOYSA-N 0.000 claims 1
- NYUWZVUNEZTVSB-UHFFFAOYSA-N 5-benzylsulfanyl-9h-pyrido[2,3-b]indole Chemical compound C=1C=CC=2NC3=NC=CC=C3C=2C=1SCC1=CC=CC=C1 NYUWZVUNEZTVSB-UHFFFAOYSA-N 0.000 claims 1
- BKPLEKGNOVHRJX-UHFFFAOYSA-N 5-phenyl-9h-pyrido[2,3-b]indole Chemical compound C1=CC=CC=C1C1=CC=CC2=C1C1=CC=CN=C1N2 BKPLEKGNOVHRJX-UHFFFAOYSA-N 0.000 claims 1
- BIPOSFOQOCEGNA-UHFFFAOYSA-N 5-phenylsulfanyl-9h-pyrido[2,3-b]indole Chemical compound C=1C=CC=2NC3=NC=CC=C3C=2C=1SC1=CC=CC=C1 BIPOSFOQOCEGNA-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- VGPBPWRBXBKGRE-UHFFFAOYSA-N n-(oxomethylidene)hydroxylamine Chemical compound ON=C=O VGPBPWRBXBKGRE-UHFFFAOYSA-N 0.000 claims 1
- ABHMZXIVLIIAIP-UHFFFAOYSA-N n-[3-(9h-pyrido[2,3-b]indol-5-yl)phenyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=CC=CC(C=2C=3C4=CC=CN=C4NC=3C=CC=2)=C1 ABHMZXIVLIIAIP-UHFFFAOYSA-N 0.000 claims 1
- INKIZSXBTRLIHN-UHFFFAOYSA-N n-[4-(9h-pyrido[2,3-b]indol-5-ylsulfanyl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=CC=CC2=C1C1=CC=CN=C1N2 INKIZSXBTRLIHN-UHFFFAOYSA-N 0.000 claims 1
- CXHDRBWMWUKPGJ-UHFFFAOYSA-N n-cyclopropyl-3-(9h-pyrido[2,3-b]indol-5-yl)benzenesulfonamide Chemical compound C=1C=CC(C=2C=3C4=CC=CN=C4NC=3C=CC=2)=CC=1S(=O)(=O)NC1CC1 CXHDRBWMWUKPGJ-UHFFFAOYSA-N 0.000 claims 1
- 230000007106 neurocognition Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Spoj formule (I): ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat; naznačen time što: R1 je -Y1-R12,svaki Y1 i Y3 nezavisno je odsutan ili linker koji osigurava razdvojenost od 1 ili 2 atoma između R12 ili R14 i prstena za koji je Y1 ili Y3 vezan, pri čemu su atomi koji osiguravaju razdvojenost izabrani iz grupe koju čine ugljik, kisik, dušik i sumpor; R4 je izabran iz grupe koju čine vodik, halo, nitro, cijano, tio, oksi, hidroksi, karboniloksi, alkoksi, karbonil, amino, (C1-5)alkilamino, (C1-5)alkil, halo(C1-5)alkil, karbonil(C1-3)alkil, sulfonil(C1-3)alkil, amino(C1-5)alkil, aril(C1-5)alkil, heteroaril(C1-5)alkil, (C3-6)cikloalkil i hetero(C3-6)cikloalkil, svaki nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A; R5 je izabran iz grupe koju čine vodik, halo i (C1-5)alkil, nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A; R6 je izabran iz grupe koju čine vodik, halo, amino, karbonil, alkoksi i (C1-5)alkil, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A; R7 je izabran iz grupe koju čine vodik, halo, hidroksi, alkoksi, amino i (C1-5)alkil, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A; svako R12 i R13 nezavisno su izabrani iz grupe koju čine vodik, halo, nitro, cijano, tio, oksi, hidroksi, alkoksi, ariloksi, heteroariloksi, karbonil, amino, (C1-10)alkilamino, sulfonamid, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino(C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A, ili R12 i R13 su uzeti zajedno tako da formiraju prsten; R14 je izabran iz grupe koju čine (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A; Grupu A čine aldehidna, aliciklična, alifatična, (C1-10)alkil, alkilen, alkiliden, amidna, amino, aminoalkil, aromatična, aril, bicikloalkil, bicikloaril, karbamoil, karbociklil, karboksil, karbonil grupa, cikloalkil, cikloalkilen, esterske, halo, heterobicikloalkil, heterocikloalkilen, heteroaril, heterobicikloaril, heterocikloalkil, oksol, hidroksi, iminoketon, keton, nitro, oksa alkil i oksolalkil grupe, pri čemu su svaka od njih nesupstituirane ili supstituirane pomoću supstituenta koji je izabran iz Grupe B;
Claims (29)
1. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat;
naznačen time što:
R1 je -Y1-R12,
svaki Y1 i Y3 nezavisno je odsutan ili linker koji osigurava razdvojenost od 1 ili 2 atoma između R12 ili R14 i prstena za koji je Y1 ili Y3 vezan, pri čemu su atomi koji osiguravaju razdvojenost izabrani iz grupe koju čine ugljik, kisik, dušik i sumpor;
R4 je izabran iz grupe koju čine vodik, halo, nitro, cijano, tio, oksi, hidroksi, karboniloksi, alkoksi, karbonil, amino, (C1-5)alkilamino, (C1-5)alkil, halo(C1-5)alkil, karbonil(C1-3)alkil, sulfonil(C1-3)alkil, amino(C1-5)alkil, aril(C1-5)alkil, heteroaril(C1-5)alkil, (C3-6)cikloalkil i hetero(C3-6)cikloalkil, svaki nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A;
R5 je izabran iz grupe koju čine vodik, halo i (C1-5)alkil, nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A;
R6 je izabran iz grupe koju čine vodik, halo, amino, karbonil, alkoksi i (C1-5)alkil, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A;
R7 je izabran iz grupe koju čine vodik, halo, hidroksi, alkoksi, amino i (C1-5)alkil, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A;
svako R12 i R13 nezavisno su izabrani iz grupe koju čine vodik, halo, nitro, cijano, tio, oksi, hidroksi, alkoksi, ariloksi, heteroariloksi, karbonil, amino, (C1-10)alkilamino, sulfonamid, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino(C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A, ili R12 i R13 su uzeti zajedno tako da formiraju prsten;
R14 je izabran iz grupe koju čine (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A;
Grupu A čine aldehidna, aliciklična, alifatična, (C1-10)alkil, alkilen, alkiliden, amidna, amino, aminoalkil, aromatična, aril, bicikloalkil, bicikloaril, karbamoil, karbociklil, karboksil, karbonil grupa, cikloalkil, cikloalkilen, esterske, halo, heterobicikloalkil, heterocikloalkilen, heteroaril, heterobicikloaril, heterocikloalkil, oksol, hidroksi, iminoketon, keton, nitro, oksa alkil i oksolalkil grupe, pri čemu su svaka od njih nesupstituirane ili supstituirane pomoću supstituenta koji je izabran iz Grupe B; i
Grupu B čine halo, nitro, cijano, tio, oksi, hidroksi, karboniloksi, (C1-10)alkoksi, (C4-12)ariloksi, hetero(C1-10)ariloksi, karbonil, oksikarbonil, aminokarbonil, amino, (C1-10)alkilamino, sulfonamido, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, hidroksi(C1-10)alkil, karbonil(C1-10)alkil, tiokarbonil(C1-10)alkil, sulfonil(C1-10)alkil, sulfinil(C1-10)alkil, (C1-10)azaalkil, imino(C1-10)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-10)alkil, aril(C1-10)alkil, hetero(C1-10)aril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, (C4-12)aril, hetero(C1-10)aril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril.
2. Spoj prema patentnom zahtjevu 1, formule (IA):
[image]
naznačen time što
n je izabran iz grupe koju čine 0, 1, 2, 3 i 4; i
R15 je izabran iz grupe koju čine vodik, halo, nitro, cijano, tio, oksi, hidroksi, alkoksi, ariloksi, heteroariloksi, karbonil, amino, (C1-10)alkilamino, sulfonamido, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A, ili bilo koja dva R15 uzeti su zajedno tako da formiraju prsten.
3. Spoj prema patentnom zahtjevu 1, formule (IB):
[image]
naznačen time što
n je izabran iz grupe koju čine 0, 1, 2, 3 i 4; i
R15 je izabran iz grupe koju čine vodik, halo, nitro, cijano, tio, oksi, hidroksi, alkoksi, ariloksi, heteroariloksi, karbonil, amino, (C1-10)alkilamino, sulfonamido, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A, ili bilo koja dva R15 uzeti su zajedno tako da formiraju prsten.
4. Spoj prema patentnom zahtjevu 1, formule (IC):
[image]
naznačen time što
R16 je izabran iz grupe koju čine amino, (C1-10)alkilamino, (C1-10)alkil, halo(C1-10)alkil, hidroksi (C1-5)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, aril i heteroaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
5. Spoj prema patentnom zahtjevu 1, formule (ID):
[image]
naznačen time što
R16 je izabran iz grupe koju čine amino, (C1-10)alkilamino, (C1-10)alkil, halo(C1-10)alkil, hidroksi(C1-5)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, aril i heteroaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
6. Spoj prema bilo kojem od patentnih zahtjeva 1-5, naznačen time što je Y1 izabran iz grupe koju čine -CH2-, -NH-, -O- i -S-.
7. Spoj prema bilo kojem od patentnih zahtjeva 1-5, naznačen time što
Y1 je izabran iz grupe koju čine -O-, -(CR19R20)m-, -NR21-, -S i -S-CH2-;
m je izabran iz grupe koju čine 0, 1, 2, 3, 4 i 5;
R19 i R20 izabrani su iz grupe koju čine vodik, halo, cijano, tio, oksi, hidroksi, karboniloksi, alkoksi, ariloksi, heteroariloksi, karbonil, oksikarbonil, aminokarbonil, amino, (C1-10)alkilamino, sulfonamido, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A, ili R19 i R12 su uzeti zajedno tako da formiraju prsten, nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A; i
R21 je izabran iz grupe koju čine vodik, karboniloksi, alkoksi, ariloksi, heteroariloksi, karbonil, oksikarbonil, (C1-10)alkilamino, sulfonamido, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A, ili R21 i R12 uzeti su zajedno tako da formiraju prsten, nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A.
8. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time što je Y3 izabran iz grupe koju čine -CH2-, -NH-, -O- i -S-.
9. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time što
Y3 je izabran iz grupe koju čine -O-, -(CR19R20)m-, -NR21-, -S i -S-CH2-;
m je izabran iz grupe koju čine 0, 1, 2, 3, 4 i 5;
R19 i R20 izabrani su iz grupe koju čine vodik, halo, cijano, tio, oksi, hidroksi, karboniloksi, alkoksi, ariloksi, heteroariloksi, karbonil, oksikarbonil, aminokarbonil, amino, (C1-10)alkilamino, sulfonamido, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil(C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicikloaril(C1-5) alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A; i
R21 je izabran iz grupe koju čine vodik, karboniloksi, alkoksi, ariloksi, heteroariloksi, karbonil, oksikarbonil, (C1-10)alkilamino, sulfonamido, imino, sulfonil, sulfinil, (C1-10)alkil, halo(C1-10)alkil, karbonil (C1-3)alkil, tiokarbonil(C1-3)alkil, sulfonil(C1-3)alkil, sulfinil(C1-3)alkil, amino (C1-10)alkil, imino(C1-3)alkil, (C3-12)cikloalkil(C1-5)alkil, hetero(C3-12)cikloalkil(C1-5)alkil, aril(C1-10)alkil, heteroaril(C1-5)alkil, (C9-12)bicikloaril(C1-5)alkil, hetero(C8-12)bicydoaril(C1-5)alkil, (C3-12)cikloalkil, hetero(C3-12)cikloalkil, (C9-12)bicikloalkil, hetero(C3-12)bicikloalkil, aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih iz grupe A.
10. Spoj prema patentnom zahtjevu 1, naznačen time što, -Y3-R14 je izabran iz grupe koju čine aril, heteroaril, (C9-12)bicikloaril i hetero(C4-12)bicikloaril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
11. Spoj prema bilo kojem od patentnih zahtjeva 1-5 i 8-10, naznačen time što je R1 izabran iz grupe koju čine vodik, halo, amino, alkoksi, karboniloksi, aminokarbonil, sulfonil, karbonilamino, sulfonilamino, (C1-10)alkil, hetero(C3-12)cikloalkil i aril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
12. Spoj prema bilo kojem od patentnih zahtjeva 1-11, naznačen time što je R2 izabran iz grupe koju čine vodik, halo, amino, alkoksi, (C1-10)alkil, hetero(C3-12)cikloalkil i aril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
13. Spoj prema bilo kojem od patentnih zahtjeva 1-12, naznačen time što je R4 izabran iz grupe koju čine vodik, halo i (C1-5)alkil, nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
14. Spoj prema bilo kojem od patentnih zahtjeva 1-12, naznačen time što, R4 je metil.
15. Spoj prema bilo kojem od patentnih zahtjeva 1-12, naznačen time što, R4 je trifluorometil.
16. Spoj prema bilo kojem od patentnih zahtjeva 1-15, naznačen time što, R6 je izabran iz grupe koju čine metil, etil, izopropil i ciklopropil, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
17. Spoj prema bilo kojem od patentnih zahtjeva 1-10 i 12-16, naznačen time što, R12 je izabran iz grupe koju čine vodik, halo, amino, alkoksi, karboniloksi, aminokarbonil, sulfonil, karbonilamino, sulfonilamino, (C1-10)alkil, hetero(C3-12)cikloalkil i aril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
18. Spoj prema bilo kojem od patentnih zahtjeva 1-11 i 13-17, naznačen time što, R13 je izabran iz grupe koju čine vodik, halo, amino, alkoksi, karboniloksi, aminokarbonil, sulfonil, karbonilamino, sulfonilamino, (C1-10)alkil, hetero(C3-12)cikloalkil i aril, pri čemu je svaki od njih nesupstituiran ili supstituiran sa jednim ili više supstituenata koji su izabrani iz grupe A.
19. Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz grupe koju čine:
5-fenil-9H-pirido[2,3-b]indol;
5-(3-(metilsulfonil)fenil)-9H-pirido[2,3-b]indol;
5-(3-(etilsulfonil)fenil)-9H-pirido[2,3-b]indol;
N-(3-(9H-pirido[2,3-b]indol-5-il)fenil)etansulfonamid;
5-m-tolil-9H-pirido[2,3-b]indol;
N-ciklopropil-3-(9H-pirido[2,3-b]indol-5-il)benzensulfonamid;
5-(3-metoksifenil)-9H-pirido[2,3-b]indol;
5-(3-(etilsulfonil)fenil)-8-metil-9H-pirido[2,3-b]indol;
5-(3-(etilsulfonil)fenil)-3,8-dimetil-9H-pirido[2,3-b]indol;
N-(4-(9H-pirido[2,3-b]indol-5-iltio)fenil)acetamid;
5-(benziltio)-9H-pirido[2,3-b]indol;
5-(feniltio)-9H-pirido[2,3-b]indol; i
5-(benziltio)-8-metil-9H-pirido[2,3-b]indol.
20. Farmaceutska kompozicija naznačena time što sadrži, kao aktivni sastojak, spoj prema bilo kojem od patentnih zahtjeva 1-19.
21. Spoj prema bilo kojem od patentnih zahtjeva 1-19, naznačen time, što se koristi za primjenu kao lijek.
22. Spoj prema bilo kojem od patentnih zahtjeva 1-19, naznačen time što se koristi za primjenu u liječenju kancera kod sisavaca.
23. Spoj prema patentnom zahtjevu 22, naznačeno time što je kancer izabran iz grupe koju čine karcinom skvamoznih stanica, astrocitom, Kapošijev sarkom, glioblastom, kancer ne-malih stanica pluća, kancer bešike, kancer glave i vrata, melanom, kancer jajnika, kancer prostate, kancer dojke, kancer malih stanica pluća, gliom, kolorektalni kancer, genitourinarni kancer, gastrointestinalni kancer, kancer tireoideje i kancer kože.
24. Spoj prema bilo kojem od patentnih zahtjeva 1-19, naznačen time što se koristi za primjenu u liječenju inflamacije, inflamatorne bolesti crijeva, psolrijaze ili odbacivanja transplanta kod sisavaca.
25. Spoj prema bilo kojem od patentnih zahtjeva 1-19, naznačen time što se koristi za primjenu u prevenciji ili liječenju amiotrofne lateralne skleroze, kortikobazalne degeneracije, Down-ovog sindroma, Huntington-ove bolesti, Parkinsoln-ove bolesti, post-encefalitičnog parkinsolnizma, progresivne supranuklearne paralize, Pick-ove bolesti, Niemann-Pick-ove bolesti, moždanog udara, traume glave i drugih kroničnih neurodegenerativnih bolesti, bipolarne bolesti, afektivnih poremećaja, depresije, šizofrenije, kognitivnih poremećaja, gubitka kose i kod primjene kontraceptivnih lijekova kod sisavaca.
26. Spoj prema bilo kojem od patentnih zahtjeva 1-19, naznačen time što se koristi za primjenu u prevenciji ili liječenju blagog oštećenja kognitivnih funkcija, oštećenja pamćenja povezanog sa starenjem, opadanja kognitivnih funkcija povezanog sa starenjem, oštećenja kognitivnih funkcija bez demencije, blagog opadanja kognitivnih funkcija, blagog opadanja neurokognitivnih funkcija, zaboravnosti u kasnom životu, oštećenja pamćenja i oštećenja kognitivnih funkcija i androgenetičke alopecije kod sisavaca.
27. Spoj prema bilo kojem od patentnih zahtjeva 1-19, naznačen time što se koristi za primjenu u prevenciji ili liječenju bolesti povezanih sa demencijom, Alzheimer-ove bolesti i stanja povezanih sa kinazama kod sisavaca.
28. Spoj prema patentnom zahtjevu 27, naznačen time što su bolesti povezane sa demencijom izabrane iz grupe koju čine frontotemporalna demencija Parkinsoln-ovog tipa, parkinsolnizam – demencija kojempleks Guam-a, HIV demencija, bolesti sa povezanim neurofibrilarnim čvorovima, predementna stanja, vaskularna demencija, demencija sa Lewy-jevim tijelima, frontotemporalna demencija i dementia pugilistica.
29. Spoj prema bilo kojem od patentnih zahtjeva 1-19, naznačen time što se koristi za primjenu u liječenju artritisa kod sisavaca.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72461905P | 2005-10-07 | 2005-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110220T1 true HRP20110220T1 (hr) | 2011-04-30 |
Family
ID=37622078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110220T HRP20110220T1 (hr) | 2005-10-07 | 2011-03-28 | Inhibitori kinaze |
Country Status (29)
Country | Link |
---|---|
US (2) | US8119655B2 (hr) |
EP (2) | EP1931669A1 (hr) |
JP (1) | JP5150878B2 (hr) |
KR (1) | KR20080051153A (hr) |
CN (1) | CN101356172B (hr) |
AT (1) | ATE495173T1 (hr) |
AU (1) | AU2006302135B2 (hr) |
BR (1) | BRPI0616950A2 (hr) |
CA (1) | CA2624610A1 (hr) |
CR (1) | CR9886A (hr) |
CY (1) | CY1111346T1 (hr) |
DE (1) | DE602006019651D1 (hr) |
DK (1) | DK2133349T3 (hr) |
EA (1) | EA015902B1 (hr) |
ES (1) | ES2358006T3 (hr) |
GE (1) | GEP20125368B (hr) |
HK (1) | HK1138842A1 (hr) |
HR (1) | HRP20110220T1 (hr) |
IL (1) | IL190306A0 (hr) |
MA (1) | MA29796B1 (hr) |
MY (1) | MY146989A (hr) |
NO (1) | NO20081564L (hr) |
NZ (1) | NZ566866A (hr) |
PL (1) | PL2133349T3 (hr) |
PT (1) | PT2133349E (hr) |
RS (1) | RS51897B (hr) |
SI (1) | SI2133349T1 (hr) |
WO (1) | WO2007044779A1 (hr) |
ZA (1) | ZA200802820B (hr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2008016184A1 (en) * | 2006-08-02 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Alpha-carboline derivatives and methods for preparation thereof |
EP2145878A3 (en) * | 2006-10-09 | 2010-02-24 | Takeda Pharmaceutical Company Limited | Aurora Kinase inhibitors |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
ES2415863T3 (es) * | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
CA2716720A1 (en) * | 2008-02-28 | 2009-09-03 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
JP2011518171A (ja) * | 2008-04-16 | 2011-06-23 | 武田薬品工業株式会社 | 5−(3−(エチルスルホニル)フェニル)−3,8−ジメチル−n−(1−メチルピペリドン−4−イル)−9h−ピリド[2,3−b]インドール−7−カルボキサミドの多形およびその使用方法 |
EP2283014A1 (en) * | 2008-04-16 | 2011-02-16 | Takeda Pharmaceutical Company Limited | Polymorphs of hydrochloride salt o5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyridoý2,3-b¨indole-7-carboxamideand methods of use therefor |
WO2009129401A1 (en) * | 2008-04-16 | 2009-10-22 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP5599784B2 (ja) | 2008-06-11 | 2014-10-01 | ジェネンテック, インコーポレイテッド | ジアザカルバゾール類と使用方法 |
BRPI0909957A2 (pt) * | 2008-06-11 | 2016-04-19 | Genentech Inc | "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero" |
AR072084A1 (es) * | 2008-06-12 | 2010-08-04 | Sanofi Aventis | Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica como inhibidores de las quinasas pim |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
JP2012512871A (ja) * | 2008-12-18 | 2012-06-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式アザインドール |
FR2950891B1 (fr) * | 2009-10-06 | 2012-11-09 | Sanofi Aventis | Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique |
FR2943674B1 (fr) * | 2009-03-24 | 2013-02-22 | Sanofi Aventis | Derives d'azacarbolines,leur preparation et leur utilisation therapeutique |
MX2011010062A (es) * | 2009-03-24 | 2011-11-18 | Sanofi Sa | Derivados de azacarbolinas 9h-pirrolo [2,3-b:5,4-c´] dipiridina, su preparacion y su uso en terapeutica. |
FR2953838B1 (fr) * | 2009-12-10 | 2012-02-24 | Sanofi Aventis | Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique |
FR2953837B1 (fr) * | 2009-12-10 | 2012-03-09 | Sanofi Aventis | Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique |
US20110183938A1 (en) | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
CN102372707B (zh) * | 2010-08-16 | 2015-08-19 | 上海药明康德新药开发有限公司 | 6-甲基-4-溴-1,6-二氢吡咯[2,3-c]吡啶-7-酮的合成方法 |
RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
RU2659786C2 (ru) | 2012-05-15 | 2018-07-04 | Кансер Ресёрч Текнолоджи Лимитед | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения |
PL2810931T3 (pl) | 2013-06-06 | 2018-09-28 | Solvay Sa | Sposób otrzymywania halogenowanych bezwodników kwasów karboksylowych |
CA2975605C (en) | 2015-02-02 | 2023-12-12 | Forma Therapeutics, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
WO2016187767A1 (en) * | 2015-05-25 | 2016-12-01 | Hutchison Medipharma Limited | Pharmaceutical compositions and use thereof |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
WO2019213506A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
MX2021001752A (es) * | 2018-08-14 | 2021-06-23 | Osteoqc Inc | Compuestos de pirrolo-dipiridina. |
US11903949B2 (en) | 2018-08-14 | 2024-02-20 | Ossifi Therapeutics Llc | Fluoro beta-carboline compounds |
US11773093B1 (en) | 2023-01-19 | 2023-10-03 | King Faisal University | N-(pyrimido[2,3-b]indol-7-yl)acetamide compounds as antibacterial agents |
Family Cites Families (302)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB828847A (en) | 1956-12-14 | 1960-02-24 | Ilford Ltd | Improvements in or relating to cyanine dyes |
FR1242962A (fr) | 1959-08-25 | 1960-10-07 | Kodak Pathe | Nouveau procédé pour la préparation de colorants sensibilisateurs de la série des cyanines et des mérocyanines et produits obtenus |
GB1268773A (en) | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
DE2844606A1 (de) | 1978-10-13 | 1980-04-24 | Bayer Ag | Heterocyclische farbstoffe |
GB2013703B (en) | 1978-01-25 | 1982-06-03 | Bayer Ag | Heterocyclic dyestuffs |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
DK0836605T3 (da) * | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
AU716330B2 (en) | 1995-12-18 | 2000-02-24 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
US7119174B2 (en) | 1995-12-18 | 2006-10-10 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
WO1998006719A1 (en) * | 1996-08-09 | 1998-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | 4-substituted beta-carbolines as immunomodulators |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
WO1999009160A1 (fr) | 1997-08-15 | 1999-02-25 | Chugai Seiyaku Kabushiki Kaisha | Proteines de regulation de cycle cellulaire |
ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
US6143480A (en) | 1998-09-03 | 2000-11-07 | Fuji Photo Film Co., Ltd. | Leuco dye and image recording medium containing the same |
US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
US20050113460A1 (en) | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
AU6237700A (en) | 1999-07-21 | 2001-02-13 | University Of Massachusetts | Kinase blocking polypeptides and uses thereof |
WO2001014378A1 (fr) | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2? |
RU2002110461A (ru) | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
CN1391561A (zh) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物和含有喹唑啉化合物的药物组合物 |
GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
CN100379734C (zh) | 1999-12-24 | 2008-04-09 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
AU2001228638A1 (en) | 2000-01-28 | 2001-08-07 | Astrazeneca Ab | Chemical compounds |
AU782878B2 (en) | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
BR0104424A (pt) | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
EP1134221A1 (en) | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
EP1209158A1 (en) | 2000-11-18 | 2002-05-29 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines |
AU3741801A (en) * | 2000-03-15 | 2001-09-24 | Aventis Pharma Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
JP2001294772A (ja) | 2000-04-10 | 2001-10-23 | Fuji Photo Film Co Ltd | 着色組成物、インクジェット用インク及びインクジェット記録方法 |
JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
US6555329B2 (en) | 2000-06-09 | 2003-04-29 | Boehringer Ingelheim International Gmbh | Method for identifying compounds altering higher-order chromatin-dependent chromosome stability |
US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
PL360439A1 (en) | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
AU2002222933A1 (en) | 2000-07-13 | 2002-01-30 | Millennium Pharamaceuticals, Inc. | Inhibitors of factor xa |
US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
AU2001287654B2 (en) | 2000-08-10 | 2006-12-14 | Pfizer Italia S.R.I. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US6352858B1 (en) | 2000-09-11 | 2002-03-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of BTAK expression |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
HUP0302173A2 (hu) | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Protein kináz inhibitorokként alkalmazható pirazolvegyületek |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002048114A1 (en) | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
EP1337521B1 (en) | 2000-11-28 | 2006-09-27 | Pfizer Products Inc. | Salts of an isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
FR2818278B1 (fr) | 2000-12-20 | 2003-02-28 | Sod Conseils Rech Applic | Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
JP2004516297A (ja) | 2000-12-20 | 2004-06-03 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) | サイクリン依存性キナーゼ(cdk)及びグリコーゲンシンターゼキナーゼ−3(gsk−3)の阻害剤 |
ES2265452T3 (es) | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
JP3779682B2 (ja) | 2001-05-14 | 2006-05-31 | ファイザー・プロダクツ・インク | 5,8,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11),3,5,7,9−ペンタンの酒石酸塩及びその医薬組成物 |
JPWO2002094809A1 (ja) | 2001-05-24 | 2004-09-09 | 山之内製薬株式会社 | 3−キノリン−2(1h)−イリデンインドリン−2−オン誘導体 |
AU2002310187A1 (en) | 2001-05-30 | 2002-12-09 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
US6762179B2 (en) | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
ES2274035T3 (es) | 2001-06-01 | 2007-05-16 | Vertex Pharmaceuticals Incorporated | Compuestos de tiazol utiles como inhibidores de proteina quinasas. |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
EP1404799A1 (en) | 2001-06-22 | 2004-04-07 | The Procter & Gamble Company | Fabric care compositions for lipophilic fluid systems |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
DE60216097T2 (de) | 2001-07-19 | 2007-06-28 | Pfizer Italia S.R.L. | Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel |
WO2003009852A1 (en) | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003012046A2 (en) | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Stk15 (stk6) gene polymorphism and methods of determining cancer risk |
WO2003011287A1 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
CA2455631A1 (en) | 2001-08-06 | 2003-02-20 | Pharmacia Italia S.P.A. | Aminoisoxazole derivatives active as kinase inhibitors |
US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
US6927293B2 (en) | 2001-08-30 | 2005-08-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
AU2002341729A1 (en) | 2001-09-19 | 2003-04-01 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
MXPA04002682A (es) | 2001-09-19 | 2004-06-18 | Pharmacia Corp | Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion. |
US6849653B2 (en) | 2001-09-19 | 2005-02-01 | Pharmacia Corporation | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
BR0212613A (pt) | 2001-09-19 | 2004-08-31 | Pharmacia Corp | Compostos de indazol substituìdos para o tratamento de inflamação |
CZ2004359A3 (cs) | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty |
GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
JP4460292B2 (ja) | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
US20040010027A1 (en) | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
IL162541A0 (en) | 2001-12-24 | 2005-11-20 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
CA2472341C (en) | 2002-02-01 | 2011-06-21 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds & uses thereof |
FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
EP1485376B1 (en) | 2002-03-15 | 2007-06-27 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
DE60332433D1 (de) | 2002-03-15 | 2010-06-17 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
CA2480880C (en) | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
AU2003244978A1 (en) | 2002-04-15 | 2003-10-27 | Inserm | Methods to identify anti-tumoral agents inhibiting rasgap / aurora kinase interactions |
AU2003237121A1 (en) | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
ES2340475T3 (es) | 2002-05-01 | 2010-06-04 | Vertex Pharmaceuticals Incorporated | Estructura cristalizada de proteina aurora-2 y sus bolsillos de union. |
EP1506176B1 (en) | 2002-05-17 | 2013-04-24 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
WO2003101983A1 (fr) * | 2002-05-31 | 2003-12-11 | Yamanouchi Pharmaceutical Co., Ltd. | Derive tetrahydropyrane |
US6989451B2 (en) | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
FR2840905B1 (fr) | 2002-06-12 | 2006-07-07 | Centre Nat Rech Scient | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
AU2002311176A1 (en) | 2002-06-12 | 2003-12-31 | Axia Biosciences, Inc. | Chfr protein-catalyzed polyubiquitination of aurora kinase a and aurora kinase b |
CA2486215A1 (en) | 2002-06-14 | 2003-12-24 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US20040197792A1 (en) | 2002-07-15 | 2004-10-07 | Sugen, Inc. | Novel Kinases |
MXPA05000629A (es) | 2002-07-17 | 2005-04-25 | Pharmacia Italia Spa | Derivados de pirazol heterobiciclico como inhibidores de cinasa. |
US7541378B2 (en) | 2002-07-25 | 2009-06-02 | Pfizer Italia S.R.L. | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
AU2003244632A1 (en) | 2002-07-25 | 2004-02-25 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
NZ538715A (en) | 2002-08-14 | 2007-07-27 | Vertex Pharma | Protein kinase inhibitors and uses thereof |
DE60317353T2 (de) | 2002-09-23 | 2008-08-28 | Schering Corp. | Imidazopyrazine als cdk-inhibitoren |
WO2004035577A2 (en) | 2002-10-16 | 2004-04-29 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
US6909001B2 (en) | 2002-12-12 | 2005-06-21 | Pharmacia Corporation | Method of making tricyclic aminocyanopyridine compounds |
UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
AU2003292435A1 (en) | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
CA2508921A1 (en) | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Quinazoline compounds |
ES2290529T3 (es) | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
US20060058325A1 (en) | 2002-12-24 | 2006-03-16 | Astrazeneca Ab | Therapeutic quniazoline derivatives |
CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
WO2004070062A2 (en) | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
EP1592389B1 (en) | 2003-02-14 | 2009-04-22 | Laboratoires Serono SA | Piperazine-2-carboxamide derivatives |
JP2006517949A (ja) | 2003-02-17 | 2006-08-03 | ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ | キナーゼ阻害剤としての四環系ピラゾール誘導体、前記誘導体の製造方法、および前記誘導体を含む医薬組成物 |
EP1599478B1 (de) | 2003-02-26 | 2007-05-09 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
WO2006018628A1 (en) | 2003-03-07 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
WO2004080457A1 (en) | 2003-03-11 | 2004-09-23 | Pharmacia Italia S.P.A. | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
JP4808154B2 (ja) | 2003-03-13 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用な組成物 |
CA2520465A1 (en) | 2003-03-28 | 2004-10-14 | Scios Inc. | Bi-cyclic pyrimidine inhibitors of tgf.beta. |
EP1608652A1 (en) | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
WO2004090106A2 (en) | 2003-04-04 | 2004-10-21 | Vertex Pharmaceuticals Incorporated | Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design |
JP2006522824A (ja) * | 2003-04-09 | 2006-10-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患を処置するために有用なβ−カルボリン |
ATE427308T1 (de) * | 2003-04-11 | 2009-04-15 | Glenmark Pharmaceuticals Sa | Neue heterozyklische verbindungen, die sich fur die behandlung von entzundlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten |
AU2004232527A1 (en) | 2003-04-16 | 2004-11-04 | Astrazeneca Ab | Chemical compounds |
CA2522262A1 (en) | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
WO2004096130A2 (en) | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
DE602004023838D1 (de) | 2003-04-24 | 2009-12-10 | Merck & Co Inc | Hemmer der akt aktivität |
US20040242559A1 (en) | 2003-04-25 | 2004-12-02 | Aventis Pharma S.A. | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors |
EP2385041B1 (en) | 2003-05-01 | 2013-09-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
MXPA05011741A (es) | 2003-05-01 | 2006-05-12 | Univ Michigan | Composiciones y metodos que se relacionan con compuestos y objetivos novedosos de los mismos. |
WO2005000200A2 (en) | 2003-05-09 | 2005-01-06 | Sugen, Inc. | Novel kinases |
PL1636236T3 (pl) | 2003-05-22 | 2014-02-28 | Nerviano Medical Sciences Srl | Pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz |
US7345046B2 (en) | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
ES2308182T3 (es) | 2003-06-02 | 2008-12-01 | Astrazeneca Ab | Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer. |
TW200505452A (en) | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
MXPA05013142A (es) | 2003-06-20 | 2006-03-17 | Chiron Corp | Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer. |
US20050065171A1 (en) | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
EP1641775B1 (en) | 2003-07-03 | 2009-02-18 | Euro-Celtique S.A. | 2-pyridine alkyne derivatives useful for treating pain |
GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
WO2005002571A1 (en) | 2003-07-03 | 2005-01-13 | Cambridge University Technical Services Ltd | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
EP1648900A4 (en) | 2003-07-11 | 2010-02-10 | Ariad Pharma Inc | PHOSPHORUS MACROCYCLES |
AU2004260738B2 (en) | 2003-07-16 | 2009-07-16 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
EA011300B1 (ru) | 2003-07-16 | 2009-02-27 | Янссен Фармацевтика Н.В. | Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3 |
ATE455772T1 (de) | 2003-07-21 | 2010-02-15 | Merck Serono Sa | Alkinylarylcarbonsäureamide |
US20050143371A1 (en) * | 2003-07-23 | 2005-06-30 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
PL1648878T3 (pl) | 2003-07-24 | 2009-10-30 | Euro Celtique Sa | Związki piperydynowe i zawierające je kompozycje farmaceutyczne |
US7619059B2 (en) | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
US20050026984A1 (en) | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
WO2005012262A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
BRPI0412351A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | derivados e piridilamino-pirimidina como inibidores de proteìna quinase |
US7094791B2 (en) | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
US7279575B2 (en) | 2003-08-08 | 2007-10-09 | Pfizer Italia S.R.L. | Pyrimidylpyrrole derivatives active as kinase inhibitors |
WO2005019190A2 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
JP2007505085A (ja) | 2003-09-12 | 2007-03-08 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | ベンゾイミダゾールアセトニトリル |
US20080234263A1 (en) | 2003-09-16 | 2008-09-25 | Laurent Francois Andre Hennequin | Quinazoline Derivatives |
JP4795952B2 (ja) | 2003-09-16 | 2011-10-19 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
WO2005026157A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
CA2539064A1 (en) | 2003-09-17 | 2005-04-21 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
KR20070064414A (ko) | 2003-09-17 | 2007-06-20 | 이코스 코포레이션 | 세포 증식 제어를 위한 chk1 억제제의 용도 |
DE602004021611D1 (de) | 2003-09-19 | 2009-07-30 | Gilead Sciences Inc | Azachinolinolphosphonatverbindungen als integraseinhibitoren |
US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
DE602004005881T2 (de) | 2003-10-14 | 2008-01-17 | Pharmacia Corp. | Substituierte pyrazinonverbindungen zur behandlung von entzündungen |
PT1678166E (pt) | 2003-10-14 | 2009-10-30 | Supergen Inc | Inibidores de proteína-quinase |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
EP1678169B1 (en) | 2003-10-17 | 2009-07-22 | Astrazeneca AB | 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer |
AU2004285745A1 (en) | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy |
WO2005037797A1 (en) | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
JP2007509126A (ja) | 2003-10-23 | 2007-04-12 | ファルマシア・コーポレーション | 炎症の治療のためのピリミジン化合物 |
WO2005044270A1 (en) | 2003-11-04 | 2005-05-19 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
DK1692113T3 (en) | 2003-11-14 | 2018-01-08 | Lorus Therapeutics Inc | ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
JP2007521331A (ja) | 2003-11-19 | 2007-08-02 | シグナル ファーマシューティカルズ,エルエルシー | 複数キナーゼの標的化による疾患及び障害の治療方法 |
JP4728965B2 (ja) | 2003-12-17 | 2011-07-20 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | プロテインキナーゼモジュレーターとしての二環ピラゾロ−縮合化合物 |
FR2864084B1 (fr) | 2003-12-17 | 2006-02-10 | Aventis Pharma Sa | Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
WO2005071419A2 (en) | 2004-01-16 | 2005-08-04 | Ipsogen | Protein expression profiling and breast cancer prognosis |
JP2007518822A (ja) | 2004-01-23 | 2007-07-12 | カイロン コーポレイション | 抗癌剤としてのテトラヒドロカルボリン化合物 |
TW200526204A (en) | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
FR2865934B1 (fr) | 2004-02-05 | 2006-05-05 | Sanofi Synthelabo | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
AR047969A1 (es) | 2004-02-25 | 2006-03-15 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
US20050288347A1 (en) | 2004-03-26 | 2005-12-29 | Hodge Carl N | Certain triazole-based compounds, compositions, and uses thereof |
ES2398712T3 (es) | 2004-03-30 | 2013-03-21 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de JAK y otras proteínas quinasas |
EP1740184A1 (en) | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
FR2868421B1 (fr) | 2004-04-01 | 2008-08-01 | Aventis Pharma Sa | Nouveaux benzothiazoles et leur utilisation comme medicaments |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
EP1763524A1 (en) | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
WO2005105777A1 (en) | 2004-05-05 | 2005-11-10 | Pharmacia & Upjohn Company Llc | Substituted thiophene amide compounds for the treatment of inflammation |
ES2505090T3 (es) | 2004-05-07 | 2014-10-09 | Amgen Inc. | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer |
RS50568B8 (sr) | 2004-05-14 | 2019-08-30 | Millennium Pharm Inc | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze |
CA2566531A1 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
WO2005113550A1 (ja) | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | アミノピリミジン誘導体及びその医薬としての用途 |
ATE404536T1 (de) | 2004-05-21 | 2008-08-15 | Novartis Vaccines & Diagnostic | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
JP2008500057A (ja) | 2004-05-27 | 2008-01-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh経路の阻害をモニタリングするためのバイオマーカー |
US20070254877A1 (en) | 2004-06-02 | 2007-11-01 | Takada Pharmaceutical Company Limited | Indole Derivative and Use for Treatment of Cancer |
BRPI0511065A (pt) | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
WO2005120509A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
US20080153869A1 (en) | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
CA2568756A1 (en) | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Substituted quinazolones as anti-cancer agents |
WO2006002236A1 (en) | 2004-06-18 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
MXPA06015147A (es) | 2004-06-23 | 2007-03-26 | Irm Llc | Compuestos y composiciones como inhibidores de la proteincinasa. |
ATE434614T1 (de) | 2004-06-28 | 2009-07-15 | Bayer Schering Pharma Ag | 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer |
US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
US7553838B2 (en) | 2004-07-01 | 2009-06-30 | Merck & Co. Inc. | Mitotic kinesin inhibitors |
JP2008505089A (ja) | 2004-07-01 | 2008-02-21 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
EP1781653A1 (en) | 2004-07-05 | 2007-05-09 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
EP1765791A1 (en) | 2004-07-08 | 2007-03-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
AU2005261501A1 (en) | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide derivatives as inhibitors of histone deacetylase |
AU2005261487A1 (en) | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
DE102004034623A1 (de) | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP2008506714A (ja) | 2004-07-16 | 2008-03-06 | サネシス ファーマシューティカルズ, インコーポレイテッド | オーロラキナーゼインヒビターとして有用なチエノピリミジン |
US20080261821A1 (en) | 2004-07-21 | 2008-10-23 | The Regents Of Te University Of California | Mechanism-Based Crosslinkers |
EP1773830A1 (en) | 2004-07-22 | 2007-04-18 | AstraZeneca AB | Fused pyrimidones useful in the treatment and the prevention of cancer |
WO2006008545A2 (en) | 2004-07-22 | 2006-01-26 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives as protein kinase inhibitors |
BRPI0513916A (pt) | 2004-07-27 | 2008-05-20 | Sgx Pharmaceuticals Inc | moduladores de pirrol-piridina cinase |
US20090239214A1 (en) | 2004-07-30 | 2009-09-24 | Hongyue Dai | Prognosis of breast cancer patients |
AR050365A1 (es) | 2004-08-02 | 2006-10-18 | Osi Pharm Inc | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. |
US20060141549A1 (en) | 2004-08-03 | 2006-06-29 | Sudipta Mahajan | Cell-based kinase assay |
WO2006023083A1 (en) | 2004-08-12 | 2006-03-02 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
CA2575466A1 (en) | 2004-08-13 | 2006-02-23 | Genentech, Inc. | Thiazole based inhibitors of atp-utilizing enzymes |
US7723365B2 (en) | 2004-08-18 | 2010-05-25 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
JP2008510734A (ja) | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
EP1781285A2 (en) | 2004-08-18 | 2007-05-09 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
US7544677B2 (en) | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
WO2006021547A1 (de) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinone als plk (polo like kinase) inhibitoren |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
EP1784406A1 (de) | 2004-08-27 | 2007-05-16 | Boehringer Ingelheim International GmbH | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
WO2006026597A2 (en) | 2004-08-30 | 2006-03-09 | Smithkline Beecham Corporation | Novel compositions and methods of treatment |
JP2008511600A (ja) | 2004-09-01 | 2008-04-17 | アストラゼネカ アクチボラグ | キナゾリン誘導体およびB−Raf抑制剤としてそれらの使用 |
GB0419416D0 (en) | 2004-09-01 | 2004-10-06 | Inst Of Ex Botany Ascr | 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof |
AR050926A1 (es) | 2004-09-03 | 2006-12-06 | Astrazeneca Ab | Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac) |
EP1796467A4 (en) | 2004-09-24 | 2009-07-01 | Janssen Pharmaceutica Nv | INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES |
AR050948A1 (es) | 2004-09-24 | 2006-12-06 | Hoffmann La Roche | Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer. |
JP2008514635A (ja) | 2004-09-27 | 2008-05-08 | コーザン バイオサイエンシス インコーポレイテッド | 特異的キナーゼ阻害剤 |
US20060069101A1 (en) | 2004-09-27 | 2006-03-30 | Kim Kyoung S | Prodrugs of protein tyrosine kinase inhibitors |
JP5002460B2 (ja) | 2004-10-04 | 2012-08-15 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼインヒビターとして有用なラクタム化合物 |
FR2876377B1 (fr) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes |
CN101072758B (zh) | 2004-10-12 | 2013-07-31 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
BRPI0518126A (pt) | 2004-10-15 | 2008-10-28 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição |
WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
JP4973190B2 (ja) | 2004-10-29 | 2012-07-11 | Msd株式会社 | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
WO2006058074A1 (en) | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
GB0427917D0 (en) | 2004-12-21 | 2005-01-26 | Astrazeneca Ab | Chemical compounds |
ITPI20040099A1 (it) | 2004-12-24 | 2005-03-24 | Maurizio Pacini | Sistema di realizzazione di tappeto erboso mediante micro-plantule preradicate |
MX2007008008A (es) | 2004-12-30 | 2007-11-12 | Astex Therapeutics Ltd | Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora. |
WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
EP1836199A1 (en) | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases |
GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
FR2882751B1 (fr) | 2005-03-04 | 2007-09-14 | Aventis Pharma Sa | Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation |
GB0504474D0 (en) | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0504475D0 (en) | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
FR2884821B1 (fr) | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
US20070004684A1 (en) | 2005-06-09 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Alpha-Carbolines as CDK-1 inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2008016184A1 (en) | 2006-08-02 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Alpha-carboline derivatives and methods for preparation thereof |
EP2145878A3 (en) | 2006-10-09 | 2010-02-24 | Takeda Pharmaceutical Company Limited | Aurora Kinase inhibitors |
EP2081930A2 (en) | 2006-10-09 | 2009-07-29 | Takeda San Diego, Inc. | Kinase inhibitors |
US20100120717A1 (en) * | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2009129401A1 (en) * | 2008-04-16 | 2009-10-22 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
-
2006
- 2006-10-09 US US11/539,857 patent/US8119655B2/en not_active Expired - Fee Related
- 2006-10-10 DE DE602006019651T patent/DE602006019651D1/de active Active
- 2006-10-10 NZ NZ566866A patent/NZ566866A/en not_active IP Right Cessation
- 2006-10-10 ES ES09011369T patent/ES2358006T3/es active Active
- 2006-10-10 BR BRPI0616950-3A patent/BRPI0616950A2/pt not_active IP Right Cessation
- 2006-10-10 CN CN2006800461694A patent/CN101356172B/zh not_active Expired - Fee Related
- 2006-10-10 MY MYPI20080893A patent/MY146989A/en unknown
- 2006-10-10 CA CA002624610A patent/CA2624610A1/en not_active Abandoned
- 2006-10-10 KR KR1020087007956A patent/KR20080051153A/ko not_active Application Discontinuation
- 2006-10-10 EP EP06816697A patent/EP1931669A1/en not_active Withdrawn
- 2006-10-10 SI SI200630970T patent/SI2133349T1/sl unknown
- 2006-10-10 EA EA200800725A patent/EA015902B1/ru not_active IP Right Cessation
- 2006-10-10 DK DK09011369.7T patent/DK2133349T3/da active
- 2006-10-10 EP EP09011369A patent/EP2133349B1/en active Active
- 2006-10-10 AT AT09011369T patent/ATE495173T1/de active
- 2006-10-10 PT PT09011369T patent/PT2133349E/pt unknown
- 2006-10-10 RS RS20110141A patent/RS51897B/en unknown
- 2006-10-10 GE GEAP200610601A patent/GEP20125368B/en unknown
- 2006-10-10 WO PCT/US2006/039667 patent/WO2007044779A1/en active Application Filing
- 2006-10-10 ZA ZA200802820A patent/ZA200802820B/xx unknown
- 2006-10-10 AU AU2006302135A patent/AU2006302135B2/en not_active Ceased
- 2006-10-10 JP JP2008534786A patent/JP5150878B2/ja not_active Expired - Fee Related
- 2006-10-10 PL PL09011369T patent/PL2133349T3/pl unknown
-
2008
- 2008-03-19 MA MA30770A patent/MA29796B1/fr unknown
- 2008-03-19 IL IL190306A patent/IL190306A0/en unknown
- 2008-03-31 NO NO20081564A patent/NO20081564L/no not_active Application Discontinuation
- 2008-04-15 CR CR9886A patent/CR9886A/es not_active Application Discontinuation
-
2010
- 2010-02-18 US US12/708,304 patent/US8318939B2/en not_active Expired - Fee Related
- 2010-06-02 HK HK10105466.2A patent/HK1138842A1/xx not_active IP Right Cessation
-
2011
- 2011-03-21 CY CY20111100302T patent/CY1111346T1/el unknown
- 2011-03-28 HR HR20110220T patent/HRP20110220T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110220T1 (hr) | Inhibitori kinaze | |
UA92494C2 (ru) | Производные пиррола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов | |
CA2731869C (en) | Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | |
HRP20060100T3 (hr) | Derivati diaril i arilheteroaril uree kao modulatori 5-ht2a serotonin receptora korisni za profilaksu i liječenje poremećaja povezanih s njima | |
HRP20180592T1 (hr) | Novi biciklički derivati dihidrokinolin-2-ona | |
JP2015528821A5 (hr) | ||
RS54199B1 (en) | PROCEDURE FOR OBTAINING INTERMEDIERS OF USEFUL USES AS OPIOID RECEPTOR MODULATORS | |
AU2004265101B2 (en) | Gabanergic modulators | |
KR20080087070A (ko) | 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제 | |
EP2654422A1 (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
RS53176B (en) | KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS | |
AU4317899A (en) | Neuropeptide y5 receptor antagonists | |
JP2011503099A5 (hr) | ||
RS52522B (en) | 1-ALKYL-1-AZONIABICYCLE DERIVATIVES / 2.2.2. / OCTAN CARBAMATE AND THEIR USE AS AN ANTAGONIST OF MUSCAR RECEPTORS | |
AU2004311749A1 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | |
TW201311660A (zh) | 治療性化合物及相關使用方法 | |
WO2007057790A3 (en) | Substituted bicyclic pyrimidone derivatives | |
JP2010527951A (ja) | キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体 | |
AU2006256583A1 (en) | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | |
CA2624795A1 (en) | Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors | |
RU2007136783A (ru) | ГИДРАЗИНОКАРБОНИЛТИЕНО[2, 3-c]ПИРАЗОЛЫ, СПОСОБ ПОЛУЧЕНИЯ, СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ | |
AR042690A1 (es) | Derivados de pirrolil-tiazol como agonistas inversos de receptores cb1; preparacion de los mismos y composiciones farmaceuticas que los contienen | |
CA3112391A1 (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
DE69113115T2 (de) | Dioxo-tetrahydrochinolinderivate. | |
TWI809146B (zh) | 組蛋白去乙醯酶雙環抑制劑 |